Charles Baum, new Terremoto Biosciences CEO
July 25, 2024 06:00 AM EDTUpdated 09:05 AM
People

Ex­clu­sive: Af­ter sell­ing Mi­rati to BMS for near­ly $5B, Chuck Baum lands at an­oth­er ‘un­drug­gable’ com­pa­ny

Lei Lei Wu

News Reporter

Mi­rati Ther­a­peu­tics’ long­time leader Charles “Chuck” Baum has tak­en a new job as CEO of Ter­re­mo­to Bio­sciences, a Bay Area biotech that’s de­vel­op­ing drugs that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times